Compass Therapeutics

Update in progress

CMPX (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Compass Therapeutics is a clinical-stage oncology biopharmaceutical company focused on antibody-based therapies. Its lead candidate, tovecimig, is a bispecific antibody targeting DLL4 and VEGF-A to disrupt tumor blood vessel formation. The pipeline also includes CTX-471, an IgG4 antibody that agonizes CD137; CTX-8371, a PD-1/PD-L1 bispecific inhibitor; and CTX-10726, a PD-1/VEGF-A bispecific. Founded in 2014 and based in Boston.

Company score

Sentiment: 0.25; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.41; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.07; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.14; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.19; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive